Invivyd And SPEAR Study Group Initiate FLINTLOCK Phase 2 Trial Evaluating Safety, Tolerability, Pharmacokinetics, And Clinical Efficacy Of High-Dose Monoclonal Antibody VYD2311 In Individuals With Long COVID Or Post-Vaccination Syndrome

Invivyd, in collaboration with the SPEAR Study Group, has initiated the Phase 2 FLINTLOCK clinical trial to evaluate the safety, tolerability, pharmacokinetics, and clinical efficacy of its monoclonal antibody VYD2311 for individuals suffering from Long COVID or Post-Vaccination Syndrome (PVS). The trial is a randomized, double-blind, placebo-controlled study that will administer a high-dose IV infusion of VYD2311, followed by monthly IM injections, targeting a total dose significantly higher than previous studies while remaining within a safe range. The trial aims to enroll adults aged 18-65 with confirmed Long COVID or PVS and will assess clinical efficacy and safety over a 90-day period, with initial data expected by mid-2027.